期刊
ONCOLOGY
卷 58, 期 2, 页码 89-95出版社
KARGER
DOI: 10.1159/000012085
关键词
melanoma; interferon-alpha; interleukin-2; chemo-immunotherapy; EORTC
类别
Cytokine-based treatment regimens have been evaluated for advanced melanoma in a number of phase I and phase II trials within the last decade. Treatment with interleukin-2 (IL-2) as a single agent has resulted in response rates of approximately 15%, if a high dose of IL-2 is administered. Combination of interferon-alpha (IFN alpha) and high dose IL-2 yields response rates ranging from 10 to 41%, Response rates exceeding 50% have been reported with chemoimmunotherapy, if the treatment regimens included at least the three agents IL-2, IFN alpha and cisplatin, Recent randomized trials have evaluated the impact of these drugs on the survival of patients with advanced melanoma. The current 'state of the art' is discussed in this review, Copyright (C) 2000 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据